Psychedelic Biotechnology Stocks Rally Following Trump's Executive Order to Expedite Drug Research

This executive order signals a significant shift in regulatory attitudes towards psychedelic treatments, potentially unlocking new markets and investment opportunities.

• President Trump signed an executive order on April 18, 2026, to expedite FDA reviews of psychedelic drugs for serious mental illnesses.
• Psychedelic biotech stocks surged in early trading, with Enveric Biosciences shares skyrocketing by 187%.
• Federal funding of $50 million was allocated to support research and development in this sector.

• Previous FDA rejections of psychedelic therapies, such as MDMA for PTSD, highlighted regulatory hurdles that companies faced.
• State-level initiatives, like Texas's $50 million ibogaine research program, indicate growing local support for psychedelic research.
• Influential discussions with public figures, including Joe Rogan, have brought more attention to the therapeutic potential of psychedelics, despite safety concerns.

On April 18, 2026, President Trump signed the executive order titled "Accelerating Medical Treatments for Serious Mental Illness," which directs the FDA to prioritize the review of psychedelic drugs. This order establishes priority review vouchers and patient access pathways under the Right to Try Act, allowing patients to access experimental treatments more easily. The $50 million allocated for research through the Advanced Research Projects Agency for Health (ARPA-H) aims to match state-level funding initiatives, such as Texas's ibogaine program, which was launched in response to the growing recognition of psychedelics' therapeutic potential.

The surge in stock prices for companies like Enveric Biosciences (up 187%) and Compass Pathways (up to 38.9%) reflects investor optimism about reduced regulatory risks and increased funding for research. Analysts have described the executive order as an "official stamp of validation" for the psychedelic biotech sector, which has been under scrutiny due to previous FDA rejections and safety concerns, including cardiovascular risks associated with ibogaine.

The order also facilitates collaborations with the Department of Veterans Affairs (VA) for clinical trials, potentially expanding the market for these treatments. As the FDA prepares to issue priority review vouchers, the landscape for psychedelic drug development is rapidly evolving. The bipartisan support for expanded access to these treatments suggests a shift in public and political perception, which could lead to more favorable regulatory environments in the future.

Investors are closely monitoring the potential for FDA decisions on psychedelic drugs by summer 2026, with approvals anticipated between 2027 and 2030. This timeline could significantly impact the market dynamics for companies involved in psychedelic research and development.

• Investors in biotech stocks: Immediate financial gains from stock surges and increased market interest.
• Patients with mental health conditions: Potential access to new treatment options for conditions like PTSD and opioid addiction.
• Healthcare providers: Opportunities to integrate new therapies into treatment plans, pending regulatory approvals.
• State governments: Increased funding and support for local research initiatives, enhancing their healthcare offerings.

• FDA review timelines: Monitoring when the FDA will issue priority review vouchers and make decisions on psychedelic drug applications is crucial for market movements.
• Legislative developments: Watch for bipartisan efforts to expand access to psychedelic treatments, which could further legitimize the market.
• Clinical trial results: Upcoming results from ongoing trials will provide insights into the efficacy and safety of these treatments, influencing public perception and investment.